Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of ...

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

DexCom (NasdaqGS:DXCM) recently experienced a 14% price increase over the past week. This uptick coincides with the company's announcement of FDA clearance for the Dexcom G7 Continuous Glucose ...

RBC Capital lowered the firm’s price target on DexCom (DXCM) to $100 from $115 and keeps an Outperform rating on the shares as part of a ...

If you're using a Dexcom G7 to monitor your blood sugar in real-time, you can now sync it to your Apple Watch for real-time ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

San Diego-based Dexcom submitted its 15-day G7 CGM to the FDA in October 2024. The company says its 15-day G7 also meets ...